Connect your AI

Revvity RVTY Depreciation

Depreciation at other companies

Thermo Fisher ScientificTMO

——

IlluminaILMN

——

Charles River LaboratoriesCRL

——

GE HealthCare TechnologiesGEHC

——

Segments

By segment

Life Sciences$9.91M+37.9%

Diagnostics$9.56M+39.6%

Other financials

Income statement

Revenue$711.1M+7.0%

Gross profit$387.7M+3.2%

Operating income$75.9M+5.1%

Net income$40.7M-3.6%

EPS (diluted)$0.36+2.9%

Balance sheet

Cash & equivalents$861.5M-24.3%

Total debt$3.9B+17.8%

Total equity$7.2B-5.9%

Total assets$12.0B-2.9%

Cash flow

Operating cash flow$115.2M-10.1%

CapEx$19.8M+23.7%

Free cash flow$95.5M-14.9%

Valuation

Market cap$11.16B-22.9%

Enterprise value$14.24B-13.7%

P/E46.5×-4.0×

P/S3.8×-1.4×

Profitability

Gross margin48.5%—

Operating margin12.4%-1.1pp

Net margin8.3%-2.1pp

FCF margin17%-1.9pp

Returns & leverage

Return on equity3.2%-0.5pp

Debt / equity0.5×+0.1×

Current ratio1.7×-1.9×

Where this comes from

Reported directly by Revvity in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Revvity’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Revvity's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Revvity's depreciation?: Revvity (RVTY) reported depreciation of $19.98M in Q1 2026.
How has Revvity's depreciation changed year-over-year?: Revvity's depreciation increased by 35.7% year-over-year, from $14.72M to $19.98M.